Issue link: http://www.e-digitaleditions.com/i/880535
Recent news items on research and development, and progress in the treatment of respiratory diseases, including asthma, COPD, tuberculosis and others Inhalation OctOber 2017 9 In related news, PRNewswire reported that the United States Food and Drug Administration (FDA) has granted Priority Review of Kaléo's supplemental New Drug Application (sNDA) for AUVI-Q 0.1 mg, the first known epinephrine a u t o - i n j e c t o r d e s i g n e d f o r treatment of life-threatening allergic reactions in infants and small children weighing 16.5 to 33 pounds. The new 0.1 mg dose epinephrine auto-injector has a shorter needle length and lower dose than existing 0.15 mg and 0.3 mg epinephrine auto-injectors. per school per academic year. Each carton contains two epinephrine auto-injectors and a trainer device. A u v i - Q h a s v o i c e - a c t i v a t e d prompts that guide patients or their caretakers in using the device. In 2012, lawmakers in Virginia passed legislation requiring schools to keep a s u p p l y o f e p i n e p h r i n e t o administer to students in the event of a severe allergic reaction. e law was prompted by the allergic reaction death of an elementary student while at school. RespiRatoRy Medicine news Half of children do not receive epinephrine before arriving at emergency room DENVER, COLORADO—Live Science reports that only 36 percent of children who had an anaphylactic reaction received an injection of epinephrine from an auto-injector before they arrived at an emergency room or an urgent care clinic. Researchers examined medical records of more than 400 children and teens who had a severe allergic reaction and went to either the emergency room or the urgent care clinic at Nationwide Children's Hospital in Ohio. Nearly half of the patients were age five or younger. e children and teens were more likely to have received the drug prior t o a r r i v i n g a t t h e h o s p i t a l i f their allergic reaction occurred w h i l e t h e y w e r e a t s c h o o l . A m a j o r i t y i n t h e s t u d y h a d a n anaphylactic reaction in the past but less than half had been prescribed an epinephrine auto-injector. Among those who had a prescription, only approximately two-thirds had the device with them at the time of allergic reaction. The study was published in Annals of Allergy, Asthma and Immunology. Senior study author Dr. David Stukus, an allergist at Nationwide Children's Hospital cautioned, "It's vital to keep your epinephrine with you... people with [severe] allergies should also carry a second dose of the m e d i c i n e . W h e n i n d o u b t , administer [that second dose], too." Kaléo to donate epinephrine injectors to all U.S. public elementary schools RICHMOND, VIRGINIA—e Richmond Times Dispatch has reported that Kaléo Pharmaceutical Company of Richmond, Virginia is offering free Auvi-Q epinephrine auto-injectors to more than 67,000 public elementary schools in the United States. e new program is called "Q Your School" and will provide up to four Auvi-Q cartons